Testing RAG-21 for ALS with FUS gene mutations
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This trial tests a new drug called RAG-21 for people with ALS who have a specific change in their FUS gene. The goal is to see if it is safe and if it can slow down the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have ALS that started with limb weakness and have a confirmed FUS gene mutation.
- Your lung function must be at least 50% of what is expected for your age and size.
- You must not have used the drug Ulefnersen before or now.
- You must not have certain FUS mutations in a small part of the gene (nucleotides 928-970).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new gene therapy called VGN-R13 for people with ALS. It aims to see if the treatment is safe and tolerable, and if it can slow down the disease. You may be able to join if your ALS symptoms started recently and your lung function is still fairly good.
This trial tests a new gene therapy called SNUG01 for adults with ALS. It aims to see if the treatment is safe and can slow the disease. You may be eligible if you are diagnosed early (within 2 years) and have good breathing function.
This trial tests a new type of cell therapy called regulatory T cells (Tregs) for people with neurodegenerative diseases like ALS. The goal is to see if these cells can slow down the disease.
This trial tests a single injection of SNUG01 into the spinal fluid to see if it is safe and could help people with ALS. It is an early study to check for side effects and how well the treatment works.
This study tests an investigational oral medication, FHND1002, for people with ALS whose disease has been progressing for less than 2 years. It aims to slow further decline in muscle function and breathing ability.
This trial tests a new drug, RAG-17, for people with ALS who have a specific SOD1 gene mutation. The goal is to see if it's safe and how it affects the body, which may help slow the disease.
Hear when a new Amyotrophic Lateral Sclerosis (ALS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.